TABLE 2.
Summary of HGF/c-Met signaling inhibitors in clinical trials.
| Inhibitor name | Targets of inhibitor | Cancer type | Phase | Status | Clinical trial no. |
| Anti HGF antibody | |||||
| Rilotumumab (AMG 102) | HGF | Gastric cancer | Phase III | Terminated | NCT02137343 |
| Gastric cancer | Phase III | Terminated | NCT01697072 | ||
| Gastroesophageal adenocarcinoma | Phase II | Unknown | NCT01443065 | ||
| Colorectal and gastrointestinal cancer | Phase I/II | Completed | NCT00788957 | ||
| Gastric or esophagogastric junction cancer | Phase I/II | Completed | NCT00719550 | ||
| Gastric or GEJ cancer | Phase I | Completed | NCT01791374 | ||
| Ficlatuzumab (AV299) | HGF | Pancreatic cancer | Phase I | Recruiting | NCT03316599 |
| Anti c-Met antibody | |||||
| Onartuzumab (MetMAb) | c-Met | Gastric cancer | Phase III | Completed | NCT01662869 |
| Colorectal cancer | Phase II | Completed | NCT01418222 | ||
| Gastric cancer | Phase II | Completed | NCT01590719 | ||
| Hepatocellular carcinoma | Phase I | Completed | NCT01897038 | ||
| Emibetuzumab | c-Met | Advanced cancer | Phase I/II | Completed | NCT02082210 |
| Telisotuzumab–Vedotin | c-Met | Advanced solid tumors | Phase I | Recruiting | NCT02099058 |
| Small molecule c-Met kinase inhibitors | |||||
| Non-selective c-Met inhibitors (ATP competitive) | |||||
| Crizotinib | c-Met, ALK and ROS1 | c-Met positive gastric cancer | Phase II | Completed | NCT02435108 |
| Solid tumor and colorectal cancer | Phase I | Active, not recruiting | NCT02510001 | ||
| Diffuse gastric cancer or breast carcinoma | Phase II | Recruiting | NCT03620643 | ||
| Cabozantinib | c-Met, VEGFRs, RET, KIT and AXL | Hepatocellular carcinoma | Phase IV | Recruiting | NCT03963206 |
| Hepatocellular carcinoma | Phase III | Recruiting | NCT03755791 | ||
| Colorectal cancer | Phase II | Active, not recruiting | NCT03542877 | ||
| Colorectal cancer | Phase I | Completed | NCT02008383 | ||
| Pancreatic cancer | Phase I | Completed | NCT01663272 | ||
| Pancreatic adenocarcinoma | Phase II | Recruiting | NCT03213626 | ||
| Foretinib | c-Met, AXL, RON, VEGFR2 and TIE-2 | Gastric cancer | Phase II | Completed | NCT00725712 |
| Hepatocellular carcinoma | Phase I | Completed | NCT00920192 | ||
| Golvatinib (E7050) | c-Met, VEGFR-2 | Hepatocellular carcinoma | Phase I/II | Completed | NCT01271504 |
| Gastric cancer and solid tumors | Phase I/II | Terminated | NCT01355302 | ||
| Gastric cancer and solid tumors | Phase I | Completed | NCT01428141 | ||
| Selective c-Met inhibitors (ATP competitive) | |||||
| AMG 337 | c-Met | Stomach neoplasms | Phase II | Terminated | NCT02016534 |
| Phase I/II | Completed | NCT02096666 | |||
| Volitinib (Savolitinib) | c-Met | MET amplification gastric adenocarcinoma | Phase II | Recruiting | NCT02449551 |
| MET amplified metastatic or unresectable colorectal cancer | Phase II | Recruiting | NCT03592641 | ||
| Gastric adenocarcinoma with c-Met overexpression | Phase II | Recruiting | NCT02447380 | ||
| Gastric cancer | Phase I | Completed | NCT02252913 | ||
| Tepotinib (MSC2156119J) | c-Met | Hepatocellular carcinoma | Phase I/II | Completed | NCT02115373 |
| Hepatocellular carcinoma | Phase I/II | Active, not recruiting | NCT01988493 | ||
| Capmatinib | c-Met | Hepatocellular carcinoma | Phase II | Active, not recruiting | NCT01737827 |
| Hepatocellular carcinoma | Phase I/II | Active, not recruiting | NCT02795429 | ||
| Special structure c-Met inhibitors (Non-ATP competitive) | |||||
| Tivantinib (ARQ-197) | c-Met | Inoperable hepatocellular carcinoma | Phase III | Completed | NCT01755767 |
| Hepatocellular carcinoma | Phase III | Completed | NCT02029157 | ||
| Unresectable hepatocellular carcinoma | Phase II | Completed | NCT00988741 | ||
| Gastric cancer | Phase II | Completed | NCT01152645 | ||
| Pancreatic neoplasms | Phase II | Completed | NCT00558207 | ||
| Gastroesophageal cancer | Phase I/II | Completed | NCT01611857 | ||
| Hepatocellular carcinoma | Phase I | Completed | NCT00802555 | ||
| Advanced hepatocellular carcinoma | Phase I | Completed | NCT01656265 | ||